Report 97: Pfizer Obscured Myocarditis Safety Signal Specific to Young Men. FDA Did Not Notice Until May 2021

Based on the search results provided, here is a summary of the key information regarding the potential link between COVID-19 vaccines and myocarditis in young males:

Myocarditis Risk in Young Males After COVID-19 Vaccination

• Several studies have found that the risk of myocarditis (inflammation of the heart muscle) is higher in young males, especially those aged 12-24, after receiving a second dose of an mRNA COVID-19 vaccine like Pfizer or Moderna
  1
  2
  3
  .
• An analysis by the CDC found that 73% of reported myocarditis cases were in those under 30 years old, 82% occurred after the second vaccine dose, and 82% were in males
  1
  .
• Estimates suggest the risk of myocarditis may be as high as 1 in 3,000 to 1 in 6,000 vaccinated young males
  2
  .

Potential Underreporting of Myocarditis Cases

• The Vaccine Adverse Event Reporting System (VAERS) used by the CDC and FDA to track adverse events has limitations, as it is a passive reporting system where anyone can submit reports
  2
  .
• Some experts believe the actual rate of myocarditis may be higher than what is reported in VAERS, as the system likely underestimates the true incidence
  2
  3
  .
• There is also no established baseline rate of myocarditis to compare the reported cases against, making it difficult to determine if the observed rates are truly elevated
  2
  .

Potential Delay in Recognizing the Myocarditis Signal

• The search results do not directly address whether Pfizer obscured or the FDA failed to notice the myocarditis safety signal in young males until May 2021.
• However, the information provided suggests there may have been a delay in fully recognizing and communicating the elevated myocarditis risk in this population, as the CDC only reported on the higher incidence in adolescent males receiving the second vaccine dose in June 2021
  1
  2
  .

In summary, the search results indicate there is evidence of an increased risk of myocarditis, especially in young males, following COVID-19 vaccination. 

1

2

3